Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)
Status:
Completed
Trial end date:
2005-12-23
Target enrollment:
Participant gender:
Summary
This study is intended to allow physicians to check the superior clinical efficacy of Vytorin
compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement
and cardiovascular risk reduction in adult patients with dislipidemia.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin